原发性胆汁性胆管炎治疗市场 - 按药物（熊去氧胆酸、奥贝胆酸）、用途（人类、兽医）、配销通路（医院药房、药房和零售药房、在线药房） - 全球预测（ 2024 - 2032）

在肝病盛行率上升的推动下，2024-2032 年原发性胆汁性胆管炎治疗市场规模将以 7.1% 的复合年增长率成长。根据 IJPCA 的数据，肝病约占全球死亡人数的 4%，每年约有 200 万人死亡。由于人口老化、不健康的生活方式和代谢紊乱发病率增加等因素，包括原发性胆汁性胆汁性胆汁性肝病（PBC）在内的肝病变得越来越常见。由于 PBC 是一种慢性进行性肝臟疾病，因此持续的医疗照护和管理至关重要。它促使医疗保健提供者和製药公司加大研发投资，以推出新的有效治疗方案。

联合疗法的发展有利于产业前景。联合疗法可以同时针对疾病的不同方面，可能比单一疗法更有效地减少 PBC 的进展。随着越来越多的资料支持联合治疗的益处，预计联合治疗的采用将会增加，从而促进市场成长。

原发性胆汁性胆管炎治疗产业根据药物、用途、配销通路和地区进行分类。

到 2032 年，奥贝胆酸部分将获得显着的吸引力，因为它在减缓疾病进展和改善肝功能方面显示出显着功效。该药物透过活化法尼醇 X 受体 (FXR) 发挥作用，该受体在胆汁酸调节和发炎中发挥着至关重要的作用。 OCA 的成功促使正在进行的临床试验和研究探索其联合疗法的潜力及其对其他肝臟疾病的有效性，从而提高了该细分市场的份额。

由于便利性、可近性和成本较低，到 2032 年，线上药局市场将实现稳定成长。此管道对于患有原发性胆汁性胆管炎（PBC）等慢性病的患者特别有益，因为他们需要定期补充药物和进行监测。线上平台提供全面的药物资讯、病患评论和送货上门服务，提高病患对处方治疗的依从性。 COVID-19 大流行进一步加速了向数位健康解决方案的转变，越来越多的患者选择在线药房以避免在实体药房环境中潜在的暴露。

在肝病高盛行率和完善的医疗基础设施的推动下，欧洲原发性胆汁性胆管炎治疗产业规模将在 2024 年至 2032 年快速扩张。领先製药公司的存在、广泛的研究活动以及支持罕见疾病治疗的有利政府政策是推动欧洲市场的关键因素。此外，该地区对个人化医疗的关注和先进治疗解决方案的采用也促进了对 PBC 治疗的需求不断增长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 原发性胆汁性胆管炎盛行率上升
    • 增加患者对非侵入性治疗的偏好
    • 研发活动数量不断增加
    • 诊断技术不断进步
  • 产业陷阱与挑战
    • 缺乏治癒性治疗
    • 医疗保健提供者和患者的认识有限
• 成长潜力分析
• 定价分析
• 未来市场趋势
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药品分类，2021 - 2032 年

• 主要趋势
• 熊去氧胆酸
• 奥贝胆酸
• 其他药品

第 6 章：市场估计与预测：按用途分类，2021 - 2032 年

• 主要趋势
• 人类
• 兽医

第 7 章：市场估计与预测：按配销通路，2021 - 2032

• 主要趋势
• 医院药房
• 药局和零售药局
• 网路药局

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Abbott Laboratories
• Arlak Biotech Pvt. Ltd
• Cadila Pharmaceuticals
• Drag Pharma
• Gilead Sciences, Inc.
• Intercept Pharmaceuticals, Inc.
• Ipsen
• Leeford Healthcare Limited
• Lupin
• Sun Pharmaceuticals Ltd.
• Viatris, Inc. (Mylan N.V.)
• Vivaldis

The Primary Biliary Cholangitis Therapeutics Market size will grow at 7.1% CAGR during 2024-2032, driven by the rising prevalence of liver diseases. According to IJPCA, liver diseases account for approximately 4% of all deaths globally, with around 2 million deaths occurring annually. Liver diseases, including PBC, are becoming more common due to factors such as aging populations, unhealthy lifestyles, and increasing rates of metabolic disorders. As PBC is a chronic and progressive liver condition, the need for ongoing medical care and management is paramount. It is prompting healthcare providers and pharmaceutical companies to invest more in R&D to introduce new and effective therapeutic options.

The development of combination therapies is favoring the industry outlook. Combination therapies allow targeting different aspects of the disease simultaneously, potentially reducing the progression of PBC more effectively than monotherapy. As more data supports the benefits of combination treatments, their adoption is expected to increase, thereby inducing market growth.

The primary biliary cholangitis therapeutics industry is classified based on drug, use, distribution channel, and region.

The obeticholic acid segment will gain significant traction through 2032, as it has shown significant efficacy in slowing disease progression and improving liver function. The drug works by activating the farnesoid X receptor (FXR), which plays a crucial role in bile acid regulation and inflammation. The success of OCA has prompted ongoing clinical trials and research to explore its potential in combination therapies and its effectiveness in other liver diseases, boosting the segment share.

The online pharmacies segment will witness steady growth through 2032, owing to the convenience, accessibility, and often lower costs. This channel is particularly beneficial for patients with chronic conditions like PBC, who require regular medication refills and monitoring. Online platforms offer comprehensive drug information, patient reviews, and home delivery services, enhancing patient adherence to prescribed therapies. The COVID-19 pandemic has further accelerated the shift towards digital health solutions, with more patients opting for online pharmacies to avoid potential exposure in physical pharmacy settings.

Europe primary biliary cholangitis therapeutics industry size will expand at a rapid pace over 2024-2032, driven by a high prevalence of liver diseases and a well-established healthcare infrastructure. The presence of leading pharmaceutical companies, extensive research activities, and favorable government policies supporting rare disease treatments are key factors driving the market in Europe. Additionally, the region's focus on personalized medicine and the adoption of advanced therapeutic solutions are contributing to the increasing demand for PBC treatments.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360º synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of primary biliary cholangitis
    • 3.2.1.2 Increasing patient preference for non-invasive treatment
    • 3.2.1.3 Growing number of research and development activities
    • 3.2.1.4 Increasing advancement in diagnostic technologies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of curative treatment
    • 3.2.2.2 Limited awareness among healthcare providers and patients
• 3.3 Growth potential analysis
• 3.4 Pricing analysis
• 3.5 Future market trends
• 3.6 Regulatory landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Ursodeoxycholic acid
• 5.3 Obeticholic acid
• 5.4 Other drugs

Chapter 6 Market Estimates and Forecast, By Use, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Human
• 6.3 Veterinary

Chapter 7 Market Estimates and Forecast, By Distribution channel, 2021 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Drug store & retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Arlak Biotech Pvt. Ltd
• 9.3 Cadila Pharmaceuticals
• 9.4 Drag Pharma
• 9.5 Gilead Sciences, Inc.
• 9.6 Intercept Pharmaceuticals, Inc.
• 9.7 Ipsen
• 9.8 Leeford Healthcare Limited
• 9.9 Lupin
• 9.10 Sun Pharmaceuticals Ltd.
• 9.11 Viatris, Inc. (Mylan N.V.)
• 9.12 Vivaldis